Harmony Biosciences Inc. (HRMY)
| Bid | 32.6 |
| Market Cap | 1.91B |
| Revenue (ttm) | 717.84M |
| Net Income (ttm) | 146.13M |
| EPS (ttm) | 2.51 |
| PE Ratio (ttm) | 13.29 |
| Forward PE | 8.89 |
| Analyst | Buy |
| Ask | 35.12 |
| Volume | 211,329 |
| Avg. Volume (20D) | 653,625 |
| Open | 33.77 |
| Previous Close | 33.21 |
| Day's Range | 32.86 - 33.77 |
| 52-Week Range | 28.14 - 41.61 |
| Beta | 0.82 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...
Analyst Forecast
According to 11 analyst ratings, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 64.87% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago · businesswire.com
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)--HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm.
3 weeks ago · businesswire.com
Harmony Biosciences to Participate in Upcoming Investor ConferencesPLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conference...